Egetis Therapeutics Ab Stock Current Valuation
| EGTX Stock | SEK 5.34 0.06 1.11% |
Valuation analysis of Egetis Therapeutics helps investors to measure Egetis Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Egetis Therapeutics' price fluctuation is relatively risky at this time. Calculation of the real value of Egetis Therapeutics is based on 3 months time horizon. Increasing Egetis Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Egetis Therapeutics' intrinsic value may or may not be the same as its current market price of 5.34, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.34 | Real 4.32 | Hype 5.34 | Naive 5.77 |
The intrinsic value of Egetis Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Egetis Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Egetis Therapeutics AB helps investors to forecast how Egetis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Egetis Therapeutics more accurately as focusing exclusively on Egetis Therapeutics' fundamentals will not take into account other important factors: Egetis Therapeutics AB Company Current Valuation Analysis
Egetis Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Egetis Therapeutics Current Valuation | 698.73 M |
Most of Egetis Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Egetis Therapeutics AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Egetis Therapeutics AB has a Current Valuation of 698.73 M. This is 95.14% lower than that of the Healthcare sector and 84.96% lower than that of the Biotechnology industry. The current valuation for all Sweden stocks is 95.8% higher than that of the company.
Egetis Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Egetis Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Egetis Therapeutics could also be used in its relative valuation, which is a method of valuing Egetis Therapeutics by comparing valuation metrics of similar companies.Egetis Therapeutics is currently under evaluation in current valuation category among its peers.
Egetis Fundamentals
| Return On Equity | -0.26 | |||
| Return On Asset | -0.14 | |||
| Operating Margin | (7.54) % | |||
| Current Valuation | 698.73 M | |||
| Shares Outstanding | 249.59 M | |||
| Shares Owned By Insiders | 52.07 % | |||
| Shares Owned By Institutions | 14.16 % | |||
| Price To Book | 1.52 X | |||
| Price To Sales | 42.39 X | |||
| Revenue | 38.24 M | |||
| Gross Profit | (58.28 M) | |||
| EBITDA | (101.9 M) | |||
| Net Income | (104.54 M) | |||
| Cash And Equivalents | 207.41 M | |||
| Cash Per Share | 1.26 X | |||
| Total Debt | 4.88 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 3.54 X | |||
| Book Value Per Share | 2.71 X | |||
| Cash Flow From Operations | (130.11 M) | |||
| Earnings Per Share | (0.70) X | |||
| Target Price | 16.2 | |||
| Number Of Employees | 17 | |||
| Beta | 1.07 | |||
| Market Capitalization | 1.51 B | |||
| Total Asset | 569.27 M | |||
| Net Asset | 569.27 M |
About Egetis Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Egetis Therapeutics AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Egetis Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Egetis Therapeutics AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Egetis Stock Analysis
When running Egetis Therapeutics' price analysis, check to measure Egetis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Egetis Therapeutics is operating at the current time. Most of Egetis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Egetis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Egetis Therapeutics' price. Additionally, you may evaluate how the addition of Egetis Therapeutics to your portfolios can decrease your overall portfolio volatility.